TRANSPLANTATION & CELLULAR THERAPY MEETINGS OF ASTCT AND CIBMTR

Filter by content:

  • Types
    • Newly diagnosed multiple myeloma
    • Relapsed/refractory multiple myeloma
  • Therapeutics
    • Auto-HSCT
    • CAR therapy
    • Ciltacabtagene autoleucel
    • Idecabtagene vicleucel
    • Lenalidomide
    • P-BCMA-ALLO1
  • Congresses
    • CAR-T 2024
    • TCT 2023
    • TCT 2024
    • TCT 2025
  • Trials
    • CARTITUDE-2
    • CARTITUDE-4
  • Expert Opinions
    • Surbhi Sidana
  • Educational Resources

Articles

  1. 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR congress coverage

    • Date: Feb 21, 2025

  2. Integrating cilta-cel into earlier lines of therapy: Rationale and latest data from CARTITUDE-2 and CARTITUDE-4

    • Date: Apr 1, 2024

  3. CARTITUDE-2 cohorts A and B: Updated efficacy and safety results

    • Date: Mar 7, 2024

  4. Are CAR T-cell therapies safe for patients with impaired renal function?

    • Date: Jul 11, 2023

  5. Chronic opioid use following auto-HSCT in patients with MM

    • Date: Mar 13, 2023

All Congresses